Data Insights

SYSA-1801 by Elevation Oncology for Solid Tumor: Likelihood of Approval

SYSA-1801 is under clinical development by Elevation Oncology and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - SYSA-1801 in Solid Tumor

Data Insights

SYSA-1801 by Elevation Oncology for Pancreatic Cancer: Likelihood of Approval

SYSA-1801 is under clinical development by Elevation Oncology and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - SYSA-1801 in Pancreatic Cancer

Data Insights

SYSA-1801 by Elevation Oncology for Metastatic Pancreatic Cancer: Likelihood of Approval

SYSA-1801 is under clinical development by Elevation Oncology and currently in Phase I for Metastatic Pancreatic Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - SYSA-1801 in Metastatic Pancreatic Cancer

Data Insights

SYSA-1801 by Elevation Oncology for Esophageal Cancer: Likelihood of Approval

SYSA-1801 is under clinical development by Elevation Oncology and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase...

Data Insights

SYSA-1801 by Elevation Oncology for Gastric Cancer: Likelihood of Approval

SYSA-1801 is under clinical development by Elevation Oncology and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...

Data Insights

Risk adjusted net present value: What is the current valuation of Elevation Oncology's EO-3021?

EO-3021 is a monoclonal antibody conjugated commercialized by Elevation Oncology, with a leading Phase I program in Metastatic Pancreatic Cancer....

Net Present Value Model: Elevation Oncology Inc's EO-3021